SVA and SEOVF Related Headlines
Go Back- Sernova and Seraxis close $11.2M financing ahead of merger
- Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
- Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
- Sernova and Seraxis agree to merge, forming BetaNova Biosciences
- Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
- From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
SVA and SEOVF Related Press Releases
Go Back- Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
- Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
- Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
- From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
